Diploma PLC (LON:DPLM - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 4,276.46 ($57.74) and traded as high as GBX 4,668.32 ($63.03). Diploma shares last traded at GBX 4,638 ($62.62), with a volume of 112,410 shares changing hands.
Diploma Stock Performance
The stock has a market capitalization of £6.22 billion, a P/E ratio of 53.59, a P/E/G ratio of 2.82 and a beta of 0.75. The stock has a 50 day moving average of GBX 4,175.64 and a 200 day moving average of GBX 4,281.86. The company has a debt-to-equity ratio of 62.17, a quick ratio of 0.80 and a current ratio of 2.17.
Diploma (LON:DPLM - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The company reported GBX 80.20 ($1.08) earnings per share (EPS) for the quarter. Diploma had a net margin of 9.25% and a return on equity of 13.18%. Equities analysts predict that Diploma PLC will post 163.7995512 EPS for the current year.
Insider Buying and Selling at Diploma
In other Diploma news, insider Katie Bickerstaffe purchased 13 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was bought at an average price of GBX 4,982 ($67.26) per share, with a total value of £647.66 ($874.39). Also, insider Ian El-Mokadem purchased 500 shares of the stock in a transaction dated Monday, March 24th. The shares were acquired at an average cost of GBX 3,948 ($53.30) per share, for a total transaction of £19,740 ($26,650.47). Insiders bought 1,346 shares of company stock valued at $5,393,173 in the last ninety days. Company insiders own 0.52% of the company's stock.
Diploma Company Profile
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Read More
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.